EP0289508A1 - Analogues d'un activateur de plasminogene tissulaire (tpa) - Google Patents

Analogues d'un activateur de plasminogene tissulaire (tpa)

Info

Publication number
EP0289508A1
EP0289508A1 EP87900529A EP87900529A EP0289508A1 EP 0289508 A1 EP0289508 A1 EP 0289508A1 EP 87900529 A EP87900529 A EP 87900529A EP 87900529 A EP87900529 A EP 87900529A EP 0289508 A1 EP0289508 A1 EP 0289508A1
Authority
EP
European Patent Office
Prior art keywords
tpa
plasmid
domain
fragment
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP87900529A
Other languages
German (de)
English (en)
Inventor
Keith R. Marotti
Edward F. Rehberg
Nicole Y. Theriault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0289508A1 publication Critical patent/EP0289508A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • TISSUE PLASMINOGEN ACTIVATOR TISSUE PLASMINOGEN ACTIVATOR (TPA) ANALOGS BACKGROUND OF THE INVENTION Field of the Invention.
  • TPA human tissue plasminogen activator
  • the analogs are TPA-like molecules that have had the native domain regions either rearranged, deleted, added or a combination thereof.
  • the analogs are the product of the expression of recombinant deoxyribonucleic acid (DNA) also described herein.
  • the present invention describes replication and expression plasmids containing the TPA-coding DNA sequences described above and suitable host microorganisms that are capable of expressing the TPA analogs after becoming transformed with an appropriate plasmid. Background.
  • TPA has therapeutic value in treating blood clots by helping dissolve the clots as they form. Thrombolysis is the process of fibrin clot dissolution.
  • the serine protease plasmin is formed from its inactive zymogen, plasminogen.
  • Activation of plasminogen is achieved through proteolytic cleavage by a class of serine proteases called plasminogen activators.
  • These activators are present in most body fluids and initiate the activation of plasminogen to plasmin. This sets up a cascade whereby a small amount of plasminogen activator can initiate the activation of a large amount of plasminogen.
  • the plasminogen activator activates plasminogen to plasmin which then acts to degrade the fibrin clot.
  • the plasminogen activator which is physiologically important to clot lysis is TPA.
  • TPA is a serine protease with a molecular weight of approximately 66,000 daltons which is produced by the vascular endothelial cells. It is glycosylated and its only known protein substrate is plasminogen. TPA has five domains: the fibronectin finger domain (F), the growth factor domain (G), the kringle 1 domain (K1), the kringle 2 domain (K2) and the active site domain (A). One or more of these domains is responsible for the unique fibrin binding activity of TPA. In addition to its fibrin affinity, TPA activation of plasminogen is enhanced in the presence of fibrin. These properties make TPA a valuable therapeutic agent because other clot dissolving drugs such as urokinase or streptokinase do not have any specificity for the fibrin clot.
  • Human TPA has been purified and its physical characteristics have been studied.
  • Rijken et al. "Purification and Characterization of the Plasminogen Activator Secreted by Human Melanoma Cells in Culture", J. Biol. Chem., vol. 256, no. 13, pp. 7035-41 (July 10, 1981).
  • Experimental quantities of human TPA are obtainable from the culture medium of human melanoma cells.
  • Kluft, C. et al. "Largescale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells” in Advances in Biotechnological Processes, Eds. Mizrahi, A. and Wezel, A.L. 2:97-110 (1983).
  • TPA messenger ribonucleic acid
  • RNA messenger ribonucleic acid
  • Bacteria were transformed for expression of TPA by Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli.”, Nature, 301:214-21 (1983). Procedures to transform yeast to express human TPA have been described in US patent application SN 663,025 and published European patent application EP 143,081.
  • This invention relates to the improved pharmacological effects of native human tissue plasminogen activator through the rearranging of the domain regions of the protein by genetic recombination.
  • the improved effects include a longer half-life and increased fibrin affinity.
  • DNA sequences that contain unique restriction sites within the interdomain regions of TPA useful for convenient splitting and rearranging of the domains. Plasmids containing this TPA coding DNA and suitable hosts for expressing the rearranged. TPA are also disclosed. Finally the rearranged TPA proteins are described.
  • this invention describes a DNA compound consisting of nucleotide bases coding for TPA-like proteins comprising an active site and one or more domains selected from the group comprising the finger domain (F), the growth factor domain (G), the kringle 1 domain (K1) and the kringle 2 domain (K2) wherein the DNA compound: (a) contains within the nucleotide sequences encoding the interdomain regions non-native endonuclease restriction sites that are not present in the nucleotide sequences encoding the domain regions and (b) encodes a TPA-like protein having a molecular weight less than 90,000 daltons and in which no domain appears more than twice.
  • compounds of the above TPA-coding DNA in which an Xba site is inserted between nucleotide bases 187 to 198, in which an Hpal or SphI site or combination thereof is inserted between nucleotide bases 328 to 342, in which an EcoRV, Clal, or Smal site or combination thereof is inserted between nucleotide bases 442 to 462, in which an BamHI or Hpal site or combination thereof is inserted between nucleotide bases 709 to 726, and in which an MstI, SphI, or Xmalll site or combination thereof is inserted between nucleotide bases 973 to 997.
  • TPA-coding DNA sequences described above are those in which the sequence of nucleotides coding for domain regions has been altered from the native arrangement with respect to their order, occurrence or both. More specifically, there is described herein TPA coding DNA sequences in which the DNA codes for TPA-like proteins in which the domains are ordered as follows from the amino terminal end: (a) FA; (b) FGK1A; (c) FGK2A; (d) FK2A; (e) FK1K2A; (f) FK2K2A; and, (g) FGK1K2A.
  • TPA-coding DNA sequences as described above in which the sequences of nucleotides both upstream and downstream from the sequences encoding the TPA-like protein render the compound capable of being maintained in a suitable host cell. More specifically there are described herein such compounds that are also capable of permitting a suitable host cell to express TPA-like proteins especially those analogs in which the domain regions have been altered in their order, occurrence or both provided that the overall molecular weight of the expressed protein does not exceed 90,000 daltons and no domain appears more than twice.
  • vectors containing DNA coding for TPA-like proteins in which the domains are ordered as follows from the amino terminal end: (a) FA; (b) FGKIA; (c) FGK2A; (d) FK2A; (e) FK1K2A; (f) FK2K2A; (g) FK1A. or (h) FGK1K2A.
  • Suitable host microorganisms capable of maintaining the above described plasmids and for the expression of the rearranged TPA proteins are also described herein.
  • the suitable host cell is a Chinese hamster ovary (CHO) cell:.
  • TPA-like proteins consisting of an active site (A) and one or more domains selected from the group consisting of the finger domain (F), the growth factor domain (G), the kringle 1 domain (K1), and the kringle 2 domain (K2) wherein the domain regions have been altered from the native arrangement with respect to their order, occurrence or both provided that the overall molecular weight of the expressed protein does not exceed 90,000 daltons and no domain appears more than twice.
  • the following arrangements of TPA domains are preferred: (a) FA; (b) FGK1A; (c) FGK2A; (d) FK2A; (e) FK1K2A; (f) FK2K2A; and (g) FKU.
  • This invention involves a series of molecular genetic manipulations that can be achieved in a variety of known ways.
  • Two prototype genes having unique endonuclease restriction sites between the domains of TPA have been deposited in accordance with the Budapest Treaty.
  • the host microorganisms are E. coli strains containing plasmids designated pTPA-B1,2,3,4(a) and pTPA-B1,2,3,4 and illustrated in Charts 10 and 11, respectively.
  • the deposit of pTPA-B1,2,3,4(a) was made with the Northern Regional Research Center, Peoria, Illinois, USA on August 29, 1986 and assigned Accession Number NRRL B-18106.
  • the deposit of pTPA-B1,2,3,4 was made with the Northern Regional Research Center, Peoria, Illinois, USA on November 28, 1986 and assigned Accession Number NRRL B-18142.
  • the deposited plasmid should not be construed as a limitation of this invention in any manner. Although a convenient starting material, the following will detail various methods available to create the TPA analogs from alternative starting materials and is followed by specific examples of preferred methods .
  • the necessary genetic manipulations can be described as the obtaining of a cDNA of TPA, the synthesizing of blocks of oligonucleotldes containing the coding sequence of the various TPA domains with selected restriction sites in the interdomain regions, the cloning and replication of the domains in E. coll and the expression of the desired TPA analog.
  • Figures Figure 1 illustrates the specific sequence and base numbering positions for synthetic TPA DNA compared to the native cDNA.
  • the native domains are all present in their natural order in Figure 1.
  • Figure 2 compares the amino acid sequence of the native TPA to a TPA analog having all the natural domains in their normal order (see chart 11).
  • the top sequences present the native sequence of either nucleotides or amino acids with the lower sequences reflecting the modified TPA.
  • Figure 3 presents the oligonucleotldes used to synthetically build the TPA analogs.
  • Figure 4 compares the native TPA protein to the the analog described in chart 11 containing the native order of TPA domains by illustrating the amino acids and nucleotides contained within the domain regions.
  • the interdomain regions are those amino acids lying between the domains as delineated in Figure 4 (see Definitions). Throughout this document, the numbered references to either nucleotides or amino acids refer to these figures.
  • Maniatis T. et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982. The manual is hereinafter referred to as Maniatis.
  • E. coli strains are grown on Luria broth (LB) with glucose, Difco's Antibiotic Medium #2 and M9 medium supplemented with glucose and acid-hydrolyzed casein amino acids. Strains with resistance to antibiotics were maintained at the drug concentrations described in Maniatis. Transformations were performed according to the method described by Morrison, D.A. (1977), J. of Bact., 132:349-351; or by Clark-Curtiss, J.E. and Curtiss, R., 1983, In Methods in Enzyaology, 101:347-362, Vu, R., Grossman, L. and Moldave, K., eds., Academic Press, New York.
  • the denaturant is allowed to diffuse upwards into the colonies for 1.5-2 minutes at which time the filters are transferred to a second bed of 3MM papers soaked in neutralizing solution containing 0.5 M Tris-HCl pH 7.4, 2 ⁇ SSC (1 ⁇ SSC - 0.15 M NaCl; 0.015 M Na Citrate; pH 7.1), and 25 mM EDTA, for 1-3 minutes. Filters are then thoroughly air dried and baked in vacuo for 2-4 hours at 80o C.
  • Hybridization conditions for oligonucleotide probes are as previously described by Goeddel, D.V. et al., Nature, vol. 290, pp. 20-26 (1981). After hybridization, the probe containing solution is removed and saved and the filters are washed in 0.1% SDS, 0.2x SSC for a total of 3 hours with 5 changes of 400 ml each. Filters are thoroughly air dried, mounted, and autoradiographed using Kodak X-OMAT AR film and Dupont Cronex Lightnening Plus intensifying screens for 16 hours at -70o C.
  • minipreps of plasmid DNA are prepared according to the method of Holmes, D. S. et al., Analyt. Biochem., vol. 114, p. 193 (1981).
  • Dideoxy sequencing is carried out according to Sanger F. et al., "Cloning in single stranded bacteriophage as an aid to rapid DNA sequencing", J. Mol. Biol. 143:161-178 (1977).
  • the dideoxy containing reactions are prepared for electrophoresing by heating to 90o for 2 min, and quenching on ice.
  • TPA cDNA was a convenient source of the active site portion of the nucleic acid sequence. Therefore it was unnecessary to chemically synthesize the active site.
  • TPA cDNA is available from a number of sources. Workers have reported preparing portions of the TPA cDNA from messenger RNA isolated from cell cultures producing large amount of TPA specifically Bowes Melanoma cells. Edlund et al., "Isolation of cDNA Sequences Coding for a Part of Human Tissue Plasminogen Activator, vol. 80, pp. 349-352 (Jan. 1983); Gronow et al., "Production of Human Plasminogen Activators by Cell Culture", Trends in Biotechnology, vol. 1, no. 1, pp. 26-29 (1983); and Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli.”, Nature, vol. 301, pp. 214-21 (20 Jan. 1983).
  • Genentech, Inc. filed a European patent application No. 0093619 on 4 May 1983, relying on the priority applications having U.S. Serial Nos. 374,860; 398,003 and 483,052 having the respective filing dates of May 5, 1982; July 14, 1982 and April 7, 1983 which is hereinafter referred to as the Genentech Application.
  • the Genentech Application discloses E. coli K12 strain 294 with ATCC No. 31446, that is a transformant having a recombinant DNA compound coding for TPA. Additionally, the E. coli K12 strain W3110 transformed by rDNA is disclosed in the Genentech Application as ATCC No.
  • the disclosures include a recombinant DNA compound useful herein.
  • disclosure of the Genentech Application provides DHFR + CHO-KI (ATCC CL 61) cells transformed for amplification also expressing TPA.
  • ATCC CL61 discloses recombinant DNA nucleotides coding for TPA useful herein.
  • Preparation 2 provides one of skill in the art with an isolation process from among the processes known in the art applicable to the Bowes melanoma cell for obtaining the recombinant DNA compound coding for a TPA.
  • the Bowes melanoma cell is commonly available to the public.
  • TPA Domains As noted above, portions of the TPA analog DNA sequences were prepared from cDNA; however, most of the sequence and even the entire sequence could have been created synthetically. Cost and convenience are the controlling parameters in deciding how to create a particular TPA analog's sequence. By selecting restriction sites not found in the TPA domains of the desired analog and by inserting these restriction sites within the interdomain regions of TPA, one avoids digesting a desired part of the TPA DNA sequence and allows for the easy removal and insertion of each individual domain. By chemically synthesizing a portion of the TPA gene, one can decide on a base by base process which nucleotides are to be used. The following advantages arise from this process: (1) the minimization of secondary structure in the transcription product; (2) the minimization of AT-GC regions of self-complementarity; and, (3) the placement of unique restriction sites at desirable locations along the cDNA sequence.
  • Oligonucleotldes are chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage S.L. and Caruthers, M.H. Tetrahedron Letts. 22(20):1859-1862 (1981) using an automated synthesizer; as described in Needham-VanDevanter, D.R., et al., Nucleic Acids Res., 12:6159-6168 (1984). Purification of oligonucleotldes was by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson, J.D. and Regnler, F.E., J. Chrom., 255:137-149 (1983).
  • Oligodeoxynucleotides are chemically synthesized in lengths of less than 40 nucleotides. Each fragment is designed to be complementary to its corresponding complementary strand and each double stranded segment contains sticky ends to optimize ligation. The following criteria are considered in the division of the DNA for synthesis of the fragments: 1) The length of the oligonucleotide fragments should be less than 40 bases in length for the ease in chemical synthesis and purification. 2) A minimal of 6 bases "protruding" from the complementing "top” and "bottom” oligonucleotide fragments appears to allow optimal alignment and ligation of the segments. 3) Regions of four bases or more which can associate with either the primary or the complement sequence should be avoided.
  • the sequence of the synthetic oligonucleotldes can be verified using the chemical degradation method of Maxam, A.M. and Gilbert, W., Grossman, L. and Moldave, D., eds., Academic Press, New York, Methods in Enzymology, 65:499-560 (1980). Alternatively, the sequence can be confirmed after the assembly of the oligonucleotide fragments into the double-stranded DNA sequence using the method of Maxam and Gilbert, supra, or the chain termination method for sequencing double-stranded templates of Wallace, R.B., et al., Gene, 16:21-26 (1981).
  • oligonucleotldes Eighty-seven separate oligonucleotldes ( Figure 3) were synthesized. The specific assembly strategy disclosed herein was to engineer the first 1099 base pairs coding for the 5' portion of the TPA analog having the selected restriction sites indicated in Chart (11). This synthetic oligonucleotide is then joined to the 3' portion of TPA cDNA at the EcoRI site at position 1287 containing the active site. To assemble the oligonucleotide fragments into the double-stranded DNA, one can mix all of the 87 fragments together for annealing and ligation. For more efficient ligation, it is better to divide the oligonucleotldes into four blocks.
  • the four blocks can then be annealed and ligated to yield the final product.
  • Purification of the assembled blocks and the final product can be performed by acrylamide gel electrophoresis as described in Maniatis. To carry out the annealing and ligation, the general methods described in Maniatis are also used. It may be necessary to provide an initiation codon for the synthetic TPA genes. For purposes of the E. coli system, the initiating codon ATG for coding for F-met is required. The initiating codon can be incorporated into the synthetic gene or be provided by the desired expression plasmid. In addition to an initiation codon, it is, for E. coli, convenient to incorporate into the synthetic gene of TPA a sequence that provides adequate spacing between the Shine-Dalgarno region and the initiation codon.
  • Cloning vectors useful for transforming E. coli include pBR322 and pKC7.
  • the native TPA cDNA does not contain sites recognized by the following endonuclease restriction enzymes in addition to those sites engineered into the two prototype cDNA of TPA illustrated in Charts 10 and 11:
  • a cloned gene e.g., the modified TPA gene
  • expression vectors which contain, at the minimum, a strong promoter to direct mRNA transcription, a ribosome binding site for translational initiation and transcription terminator. Since the accumulation of large amounts of a gene product often inhibits cell growth and sometimes causes cell death, the promoter chosen to direct the synthesis of the product must be regulated in such a way that cell growth can be allowed to reach high densities before the induction of the promoter. Examples of regulatory regions suitable for this purpose are the promoter and operator region of the E. coli tryptophan biosynthetic pathway as described by Yanofsky, C., Kelley,
  • the TPA produced in E. coli does not fold properly due to the large number of cysteine residues.
  • the E. coli-produced TPA must first be denatured and then renatured. This can be accomplished by solubilizing the
  • heterologous proteins in yeast is well known. Methods in Yeast Genetics, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods useful for producing TPA analogs in yeast.
  • a strong promoter system as in the prokaryote and to also provide efficient transcription termination/polyadenylatlon sequences from a yeast gene.
  • useful promoters include GAL1,10 (Johnston M. , and Davis, R.W., Mol. und Cell. Biol., 4:1440-48, 1984), ADH2 (Russell, D., et al., J. Biol. Chem. 258:2674-2682, 1983), PHO5 (EMBOJ. 6:675-680, 1982), and MF ⁇ 1.
  • a multicopy plasmii with a selective marker such as Lue-2, URA-3, Trp-1, and His-3 is also desirable.
  • GAL and ADH2 promoters When cells are grown on glucose, GAL and ADH2 promoters are repressed, thus, allowing cells to be grown to a high density. Whereas the GAL promoters can be turned on by transferring cells to galactose medium, ADH2 will be turned on after all the glucose has been utilized by the cells.
  • the PHO5 promoter can be switched on or off by manipulations of phosphate concentration in the medium.
  • the MF ⁇ 1 promoter in a host of the ⁇ mating-type is on all the time, but is off in diploids or cells with the a mating-type. It can, however, be regulated by raising or lowering temperature in hosts which have a ts mutation at one of the SIR loci.
  • the effect of such a mutation at 35oC on an ⁇ type cell is to turn on the normally silent gene coding for the a mating-type.
  • the expression of the silent a mating-type gene in turn, turns off the MF ⁇ 1 promoter. Lowering the temperature of growth to 27oC reverses the whole process and turns the a mating-- type off and turns the MF ⁇ 1 on (Herskowitz, I. & Oshima, Y. (1982) in The molecular biology of the yeast saccharomyces, (eds. Strathern, J.N., Jones, E.W., & Broach, J.R., Cold Spring Harbor Lab., Cold Spring Harbor, NY, pp 181-209).
  • the polyadenylation sequences are provided by the 3'-end sequences of any of the highly expressed genes, like ADH1, MF ⁇ 1, or TPI (Alber, T. and Kawasaki, G., J. of Mol. & Appl. Genet. 1:419-434, 1982).
  • a number of yeast expression plasmids like YEp6, YEp13, YEp24 can be used as vectors.
  • a gene of interest such as TPA can be fused to any of the promoters mentioned above, and then ligated to the plasmids for expression in various yeast hosts.
  • the above-mentioned plasmids have been fully described in the literature (Botstein, et al., Gene, 8:17-24, 1979; Broach, et al., Gene, 8:121-133, 1979).
  • plasmids can be and have been used to express foreign genes in yeast
  • vectors which allow significant flexibility with respect to insertion and/or excision of various components of the expression vectors.
  • One such example is the vector p ⁇ 1-ADHt illustrated in Chart 18.
  • yeast cells are first converted into protoplasts using zymolyase, lyticase or glusulase, followed by addition of DNA and poly ethylene glycol (PEG).
  • PEG poly ethylene glycol
  • the PEG-treated protoplasts are then regenerated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by J.D. Beggs, Nature (London), 275:104-109 (1978); and Hinnen, A., et al., Proc. Natl. Acad. Sci.-USA, 75:1929-1933 (1978).
  • the second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium-chloride or acetate and PEG and put on selective plates (Ito, H., et al., J. Bact., 153:163-168, 1983).
  • TPA analogs can be isolated by lysing the cells and applying standard protein isolation techniques to the lysates. TPA analogs can be detected by using Western blot techniques or radioimmunoassays.
  • the TPA analog encoding DNA can be ligated to various expression vectors for use in transforming host cell cultures.
  • the vectors all contain gene sequences to initiate transcription and translation of the TPA analogs that are compatible with the host cell to be transformed.
  • the host cell is a higher animal cell, e.g., a mammalian cell
  • the naturally occurring transcription and translation gene sequence of the TPA gene can be employed or the naturally occurring gene sequence can be employed along with a heterologous promoter sequence.
  • the vectors preferably contain a marker to provide a phenotypic trait for selection of transformed host cells.
  • a replicating vector might contain a replicon.
  • Illustrative of cell cultures useful for the production of TPA analogs are cells of insect or mammalian origin. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be vised. Illustrative examples of mammalian cell lines include VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WT38, BHK, COS-7 or MDCK cell lines. Illustrative insect cell lines include Spodoptera frugiperda (fall armyworm) and Bombyx mori (silkworm).
  • the vector e.g. a plasmld, which is used to transform the host cell, preferably contains gene sequences to initiate the transcription and translation of the TPA gene sequence. These sequences are referred to as expression control sequences.
  • expression control sequences are obtained from the SV-40 promoter (Science, 222, 524-527, (1983)), the CMV I.E. promoter (Proc. Nat'l. Acad. Sci., 81:659-663, 1984) or the metallothionein promoter (Nature, 296, 39-42 (1982)).
  • the host cell when the host cell is mammalian one may use the expression control sequences for the TPA gene but it is preferably to combine the TPA analog with a heterologous transcription initiation site.
  • the plasmid or replicating or integrating DNA material containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with cDNA coding for TPA analogs by means well known in the art.
  • polyadenylation or terminator sequences from known mammalian genes need to be incorporated into the vector.
  • An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene.
  • gene sequences to control replication in the host cell may be incorporated Into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., "Bovine papilloma virus DNA: a eukaryotic cloning vector" in DNA Cloning Vol II a practical approach. Ed. D.M. Glover, IRL Press, Arlington, Virginia pages 213-238 (1985).
  • the host cells are competent or rendered competent for transformation by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, and microinjection of the DNA directly into the cells.
  • the transformed cells are grown up by means well known in the art, Biochemical Methods in Cell Culture and Virology, Kuchler, R.
  • TPA and its analogs can be evaluated in either of two ways. The relative ability to cleave plasminogen into plasmin can be assessed and the relative ability of inhibitors to prevent production of plasmin can be assessed. The following details describe the procedures for such evaluations.
  • TPA analogs The functional activity of the TPA analogs is measured by using the coupled amidolytic assay described by Verheijen, J.H., et al., A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb. Haemostas., 48:266-269 (1982). Briefly, samples containing the TPA analogs are mixed with plasminogen and CNBr-digested fibrinogen fragments.
  • the plasmin thus formed then cleaves an exogenously added chromogenic substrate, S-2251 (H-D-Valyl-L-leucyl-L-lysine-p-nitroanilide dihydrochloride; KABI, Sweden), generating a colored product that is monitored spectrophotometrically.
  • S-2251 H-D-Valyl-L-leucyl-L-lysine-p-nitroanilide dihydrochloride
  • the effect of protease inhibitors on the activity of the TPA analogs is assessed by using a modification of this assay described by Verheijen, J.H., et al., Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb. Haemostas., 51:392-395 (1984).
  • the added inhibitor binds to the TPA, forming an irreversible complex and thereby preventing the TPA from activating the plasminogen.
  • purified native TPA is titrated with increasing amounts of an inhibitor-containing sample and the residual TPA activity is measured as outlined above.
  • a standard curve is then developed by graphically representing the residual TPA activity as a function of the amount of inhibitor-containing sample added.
  • the TPA analogs are titrated with the inhibitor.
  • the resulting curves are compared to that of the TPA standard. The degree of similarity between the curves relates directly to the susceptibility of the particular analog to inhibition.
  • TPA analogs Fibrin autography.
  • the molecular weights of the TPA analogs are estimated by subjecting samples that contain the analogs to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and when placing the acrylamide gel onto a plasminogen-containing fibrin indicator film.
  • SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
  • analog proteins diffuse from the acrylamide gel into the indicator film they convert the plasminogen into plasmin, which causes the formation of a clear zone of fibrinolysis in the otherwise opaque fibrin indicator. The appearance of this zone indicates the presence of an active TPA analog at a corresponding position in the acrylamide gel.
  • This technique also is used to assess the interaction between TPA analogs and protease inhibitors.
  • Sandwich-type enzyme-linked immunosorbent assays S-ELISAs.
  • the antigen of TPA analogs is measured immunologically by two different S-ELISAs. The first employs goat polyclonal antibodies specific for human uterine TPA. The second uses a murine monoclonal antibody. This monoclonal antibody is specifically directed against an epitope required for the activity of TPA.
  • the use of an antibody specific for the active-site domain of TPA provides an effective way of measuring the antigen of any TPA analog whose primary structure has been altered in a domain other than the active site.
  • This assay is similar to one described by Korninger, C., et al., Sandwich ELISA for TPA antigen employing a monoclonal antibody. Thromb. Res., 41:527-535 (1986). The limit of sensitivity for both of the assays is approximately 1 ng of TPA per ml.
  • TPA analogs to form complexes with inhibitors also can be assessed by using SDS-PAGE and Western immunoblotting techniques as originally described by Towbin, H., et al., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76:4350-4354 (1979). Briefly, the TPA analog is allowed to interact with the inhibitor, the mixture is subjected to SDS-PAGE, and the proteins are electrotransfered to nitrocellulose paper.
  • TPA-containing Immunocomplexes are then visualized by using I 125 -labeled protein A and autoradiography.
  • cell culture refers to the containment of growing cells derived from either a multicellular plant or animal which allows for the cells to remain viable outside the original plant or animal.
  • domain refers to a discrete continuous part of an amino acid sequence that can be equated with a particular function.
  • TPA the above cited references have defined the domain regions and Figure 4 herein discloses the approximate locations of the mid points of the interdomain regions which lie between the domains.
  • interdomain refers to the regions of a protein's amino acid sequence that lie between the domains. In this application the interdomain regions are plus or minus five amino acid residues from the mid points illustrated in Figure 4.
  • the interdomain region between the finger and growth factor domains lies between and including amino acids 44 to 55;
  • the interdomain between the growth factor and kringle 1 domains lies between and including amino acids 86 to 97;
  • the interdomain between kringle 1 and kringle 2 domains lies between and including amino acids 169 to 180;
  • the interdomain between kringle 2 and the active site lies between and including amino acids 257 to 268.
  • the term “maintained” refers to the stable presence of a plasmid within a transformed host wherein the plasmid is present as an autonomously replicating body or as an integrated portion of the host's genome.
  • microorganism includes both single cellular prokaryote and eukaryote organisms such as bacteria, actinomycetes and yeast.
  • non-native endonuclease restriction sites refers to endonuclease restriction sites that are not found at the equivalent position of the native cDNA sequence. These include both unique and nonunique sites.
  • operon is a complete unit of gene expression and regulation, including structural genes, regulator genes, and control elements in DNA recognized by regulator gene product.
  • plasmid refers to an autonomous self-replicating extrachromosomal circular DNA and includes both the expression and nonexpression types. Where a recombinant microorganism or cell culture is described as hosting an expression plasmid the term "expression plasmid” includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome(s).
  • promoter is a region of DNA involved in binding the RNA polymerase to initiate transcription.
  • DNA sequence refers to a single or double stranded DNA molecule comprised of nucleotide bases, adenosine, thymidine, cytosine and guanosine.
  • suitable host refers to a cell culture or microorganism that is compatible with a recombinant plasmid and will permit the plasmid to replicate, to be incorporated into its genome or to be expressed.
  • upstream identifies sequences proceeding in the opposite direction from expression; for example, the bacterial promoter is upstream from the transcription unit, the initiation codon is upstream from the coding region.
  • Plasmid pSK4 is an expression vector capable of directing expression of heterologous proteins in E. coli. It has a strong, regulatable promoter to mediate transcription and a strong ribosoae binding site for translation initiation. Specifically pSK4 uses the promoter and ribosome binding site (RBS) from the trpytophan (trp) operon. A unique Clal site immediately downstream from the RBS is available for insertion of desirable genes such as TPA. (Chart 3). To make plasmid pSK4, it is necessary to clone novel pTRZl (Chart 1) with pKC7, which is known (Chart 2). Rao, R.N.
  • Plasmid pTRZl contains a portion of the trp operon which includes the promoter/operator region, ribosome binding site, and a trpLE fusion ⁇ LE1413 as well as the structural genes for the galactosidase (lacZ) and lactose permease (lacY).
  • Plasmid pKC7 is a derivative of pBR322 specifying resistance to ampicillin and kanamycin and having many unique restriction endonuclease sites.
  • Plasmid pSK3 is then modified to eliminate the fused peptide sequence trpLE to yield the general expression vector pSK4.
  • Plasmid pTRZl is a clone of known plasmids pMCl403 and pWl.
  • Plasmid pMC1403 provides the lacZ gene of pTRZl minus the N-terminal eight amino acids and is fully described by Casadaban, M.J., et al., J. Bacteriol, 1980, 143: 971-980. Plasmid pMC1403 has three unique restriction enzyme cleavage sites. It is cut with EcoRI, dephosphorylated with bacterial alkaline phosphatase, and the ends are made blunt with Klenow fragment of E. coli DNA polymerase I. Plasmid pWl provides the trp promoter and operator sequence and is fully described by Nichols, B.P. and Yanofsky, C, 1983, Methods in Enzymology, eds. L. Grossman and K.
  • Plasmid pVVl contains the trp operon, with a 952 basepair deletion ( ⁇ LE1413) fusing the trp leader sequence to the trpE gene forming trpLE. Plasmid PVVl is cut with PvuII and BglII to yield fragment 2 (323 bp) which is isolated by preparative agarose gel electrophoresis. The BglII site is filled by Klenow enzyme. Fragment 2 is then ligated with pMC1403 to give pTRZl. (2) Construction of pSK3
  • the structural genes LacY and LacZ of pTRZl are unnecessary for the construction of pSK4 and their deletion will provide a smaller plasmid with more unique cloning sites. Additionally, the deletion of LacY will avoid the deleterious effects of over-production of a membrane-bound protein.
  • the trp sequences fragment 3 are excised from pTRZl by EcoRI/BamHI digestion, treated with alkaline phosphatase to minimize reinsertion, and then inserted into the EcoRI/BamHI region, fragment 4, of pKC7 which as a result of the digestion no longer specifies resistance to kanamycln.
  • pSK3 The clones having amplclllln resistance (AmpR) and kanamycln sensitivity (KanS) are screened for restriction fragments expected for the insertion of the trp promoter/operator sequence.
  • This plasmid is called pSK3 and its equivalents are as described in Chart 2.
  • the trp promoter of pSK3 still retains the trpLE peptide which is unnecessary for the construction of a direct expression vector.
  • the trpLE segment is excised by the following procedure. As described in Chart 3, the EcoRI/BamH fragment 5 carrying the trp sequences is cut from pSK3 and purified by electroelution from polyacrylamide gels. As shown, this fragment contains three TaqI sites, one of which is in the promoter/operator region, (TaqI'') and one of which is between the ribosome binding site and the start of trpLE translation (TaqI'''). The fragment is partially digested by TaqI and the entire assortment of fragments are used in a ligation reaction with pBR322 previously cleaved with both EcoRI and Clal.
  • TaqI recognizes TICGA (arrows denote point of strand scission) while Clal recognizes AT4CGAT. Since these two enzymes produce compatible cohesive ends, and the base 5' to the TaqI''' site between the ribosome binding site and trpLE is an A, (J. of Bact., 133:1457-1466) ligation of this TaqI end to the Clal end regenerates the Clal site. Note that this cloning scheme selects for single TaqI cuts and also ensures that transcription from the promoter will be in a clockwise direction. Clones displaying a 278 bp EcoRI/Clal insert, and restriction patterns characteristic of the trp promoter arc chosen and will be the equivalent of pSK4.
  • the clones are useful for the expression of protein sequences capable of translation initiation when inserted at the Clal site.
  • Preparation 2. Isolation of a Full Length cDNA Coding for Human Tissue Plasminogen Activator. A. Materials and Methods
  • Bowes represents an established cell line derived from a human spontaneous melanoma and is a gift of Dr. Daniel Rifkin of the New York University School of Medicine.
  • Cells are cultured in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 50 ⁇ g/ml gentamycin (Sigma) in a humidified atmosphere at 37o, using 95% air/5% CO 2 .
  • Cells harvested for RNA preparation are grown to confluency in Falcon 150 cm 2 flasks.
  • RNA from Bowes melanoma cells is isolated essentially as described by Lizardi, et al. Anal. Biochem., vol. 98, pp. 116-122 (1979).
  • DNA is polyA + enriched by passage over an oligodeoxythymidinecellulose (OdT-cellulose-Collaborative Research) column as described by Aviv, H. et al., Proc. Nat. Acad. Sci., vol. 69, pp. 1408-12 (1972).
  • Typical yield from 10-150 cm 2 flasks twice selected on separated OdT columns is approximately 50 ⁇ g polyA + mRNA.
  • the polyA* mRNA is fractionated by centrifugation through 15-30% linear sucrose gradients.
  • PolyA + mRNA (-300 ⁇ g) dissolved in 200-400 ⁇ l of sterile distilled H 2 O is loaded onto a gradient and centrifuged in a Beckman SW41 Ti rotor at 35,000 RPM for 18 hours, 0.5 ml fractions are collected, using the Buchler Auto Densi-Flow Model IIC to harvest from top to bottom, connected to a Gilson Micro fractionator (Model FC80-K). Aliquots from each fraction are injected into Xenopus oocytes and translation products are assayed for plasminogen activator activity by the casein-agar plate method analogous to that described by Miskin, R. et al., Nuc. Acids Res. vol. 9, pp. 3355-63. TPA activity is rendered by mRNA migrating at about 19S.
  • tissue plasminogen activator TPA is assayed by observing the conversion of plasminogen to plasmin, a non-specific protease, which digests casein.
  • the assay is performed as follows. 0.5 ml of 8% casein, boiled, is mixed with 1 ml 2 ⁇ MBS and heated to 50oC. 3% agarose is melted and cooled to 50oC. 0.5 ml of the 3% agarose is added to the casein/MBS and mixed by pipetting. 100 ⁇ l of 1 mg/ml human plasminogen is added (final concentration is 50 ⁇ g/ml) with mixing and the material is poured into a 3.5 cm diameter plastic petri dish.
  • the agarose solution is cooled to room temperature (about 30 minutes). 2 mm diameter holes in the agarose are cut with Biorad cutter gel punches. The holes are made just before use and the wells are filled with MBS.
  • One or two oocytes which have been injected with TPA RNA at least 6 hours prior to assay are added to each well. Incubation is in a humidified dish for 12-24 hours. Clear zones of casein hydrolysis are readily observed. Fractions enriched for TPA mRNA are precipitated by addition of
  • pentadecamers are preferred for vise as either probes or as primers for cDNA synthesis. Their sequences are: complementary to 3' TPA
  • EDTA in 58 ⁇ l at 90o C.
  • the mixture is allowed to equilibrate to room temperature slowly by immersion in a 5 ml water bath heated initially to 90o.
  • the pentadecamer After annealing the pentadecamer to the RNA template the following reagents are added: dithiothreitol (DTT) to 2 mM; RNasin to 1 unit/ ⁇ l final reaction volume; 100 mM Tris base, pH
  • RNA template is removed by alkaline hydrolysis as fully described in Maniatis.
  • the second strand is synthesized in a reaction consisting of 40 mM KPO 4 (K-phosphate) pH 7.5; 6.6 mM MgCl 2 ; 1 mM DTT; 500 ⁇ m each of dGTP, dTTP, dATP; 250 ⁇ m dCTP; 100 ⁇ Ci 3 H-dCTP (Amersham) and 1 unit/ ⁇ g input RNA of DNA polymerase Klenow fragment (BRL) in a final volume of 100 ⁇ l.
  • the reaction is incubated at 15o C for 4 hours and may be followed by monitoring the incorporation of 3 H-dCTP.
  • the reaction is terminated by phenol extraction, and double stranded cDNA precipitated as described above for first strand synthesis with the exception that NH 1 Ac is added to 2.5 M (rather than NaCl to 0.3 M) for the first ethanol precipitation.
  • S 1 is used to remove hairpin structures.
  • the S 1 reactions are carried out according to Maniatis. Successful elimination of hairpins is determined by an increase of TCA-soluble counts. The reaction is terminated by phenol extraction omitting the precipitations.
  • the aqueous phases are pooled and loaded directly onto sucrose gradients identical to those used for fractionation of polyA + mRNA. Fractions are collected and assayed by dissolving 5 ⁇ l aliquots into 10 ml of Aquafluor scintillation fluid (New England Nuclear) and measuring both 32 p and 3 H.
  • cDNA from relevant fractions are precipitated by addition of 2 volumes of ethanol and incubating on dry ice for 30 minutes. The precipitates are pelleted by centrifugation for 15' at room temperature in an Eppendorf microfuge. Pellets are dissolved in sterile 0.3 M NaCl, pooled and reprecipitated. The precipitates are pelleted and dried.
  • Vector DNA (prepared by digesting pBR322 to completion with Pstl and adding homopolymer tracts of dGTP residues) is commercially available from New England Nuclear.
  • the vector DNA can also be made according to the methods described by Maniatis.
  • the procedure for annealing cDNA with vector DNA is also described by Maniatis. Briefly, tailed cDNA is mixed with vector in a 1:1 molar ratio in a 50 ⁇ l reaction containing 10 mM Tris pH 7.4; 0.4 M NaCl; 1 mM EDTA. Final DNA concentrations varied between 20-60 ⁇ g/ml.
  • Annealing is accomplished by either; 1) following a defined regimen of incubations consisting of 65o/10'; 42o/60'; 37o/2 hours, and then room temperature for 2 hours, or 2) incubation at 65o/10' shutting off the water bath and allowing it to slowly equilibrate to room temperature overnight.
  • the cDNA containing vectors are introduced into E. coli using transformation procedures already described.
  • the bacteria are screened in situ using the hybridization procedures described earlier.
  • the colony hybridizations described here use the pentadecamers also described above as probes.
  • a hybridization probe on ⁇ g of 15-mer is phosphorylated in a 50 ⁇ l reaction volume consisting of 70 mM Tris-base (pH 7.6), 100 mM KCl; 10 mM MgCl 2 , 5 mM dithiothreitol, and 50 ⁇ Ci ⁇ 32 P dATP (P. L. Biochemicals), and 1 U T 4 polynucleotlde kinase (New England Biolabs). Incubation is at 37o for 60 minutes. In this fashion, the 15-mer can be labelled to specific activity of 1 x 10 8 cpm per ⁇ g.
  • Clones exhibiting complementary sequences to the probes are selected for secondary screening using Pstl restriction analysis of the clones to determine if the digestion products are consistent with the Pstl restriction map which can be obtained from the sequence given in Figure 1 or Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli.”, Nature, vol. 301, pp. 214-21 (20 Jan. 1983).
  • the desirable clones will have a large portion of the 3' portion of the TPA cDNA. Digestion yields 4 fragments: the original pBR322 vector, an 1150 bp fragment, an 80 bp fragment and a 78 bp fragment.
  • pTPA H The sequence data derived from this clone, designated pTPA H, is identical to sequence data presented by Pennica et al., Nature, vol. 301, pp. 214-21 (1983) for human tissue plasmlnogen activator (Chart 4).
  • cDNA is synthesized from twice-selected polyA + mRNA by primer extending from pentadecamer #1 rather than from OdT 12 - 18 .
  • the advantage afforded by this approach is twofold. First, because priming is specific for TPA, a higher percentage of the cDNA made should be represented by TPA specific sequences. Secondly, priming is some 800 bp 5' of the polyA tail, the site utilized by OdT 12 - 18 to prime first strand synthesis. This almost assures that the cDNA derived from this approach will include transcripts extending further 5' than pTPA H.
  • cDNA is 2.5x10 5 transformants per ⁇ g of cDNA. Two banks totaling 25,000 transformants are generated. The concept of "gene-walking" is applied to purposely bias the screening.
  • the pTPA H 5'-terminal 80 bp Pstl fragment is gel isolated and used to probe 28,000 colonies derived from the primer extended banks. This specifically selects for clones extending at least as far 5' as pTPA H, and as a result of the primer extension approach, clones containing additional 5' sequences as well.
  • the screening by in situ hybridization yields a number of positives.
  • the longest TPA insert is detected in secondary screening with Pstl and Ddel.
  • the clone, designated pTPA80-1 included an insert spanning nucleotides 550-1600 (chart 4).
  • the restriction data make it possible to determine fairly accurately (+/- ⁇ 10%) the position of the 3' terminus. If priming begins at nucleotide 1759, and pTPA80-1 has a 3' terminus at about position 1600, then a loss of approximately 160 basepairs occurs at some point during the cloning. The S 1 endonuclease is the most likely cause of the loss.
  • Plasmids pTPAH and pTPH80-1 are cut with Sad and Pvul to yield fragments 7 (1251 bp) and 8 (5.1 kb) respectively which are gel isolated.
  • the fragments are treated with bacterial alkaline phosphatase and ligated using T4 polymerase to yield pTPA3'cDNA (6.3 kb) having positions 550 to 2230 bases of the TPA cDNA.
  • the new construct is verified by Pstl digestion.
  • pTPA80-1 represents the longest TPA insert amongst the positives detected in the first primer extended banks
  • a second oligonucleotide complimentary to the coding sequence of amino acid residues 233-237 is used to generate anoirber cDNA library to complete the 5' end.
  • This particular area of the gene is chosen so that should S 1 remove even as much as 200 bp from the 3' terminus of the transcript, sufficient overlap with pTPA3'cDNA would still exist to allow for assembly of the fragments.
  • the cDNA containing the 5' bases was ligated to Pstl cleaved pBR322 and transformed in E. coli as described above.
  • Transformation efficiency with this cDNA is on the order of 3.6x10 4 transformants/ ⁇ g cDNA. Colonies from this library are screened with an oligonucleotide complimentary to coding sequence extending from nucleotides 645-660 (15-mer #3) and unambiguous positives are selected. Secondary screening is accomplished by Pstl and Bglll digestion and one clone, designated pTPA5'cDNA was shown to contain the remaining 5' sequences 1-750. Again, the effects of S 1 on insert length are apparent with pTPAS'cDNA. While priming is initiated at nucleotide 886, pTPA5'cDNA extends only to about nucleotide 750; our work showed a loss of about
  • Plasmid pTPAS'cDNA is cut with TaqI to yield fragment 9 (2194 bp).
  • One TaqI site within the TPA sequence of pTPAS'cDNA (position 634) is highly enzyme resistant.
  • Fragment 9 is cut with BglII and Hgal to yield fragment 10 (405 kb) having bases 188 to 593 of TPA cDNA representing the mature portion of the protein.
  • the middle portion of the TPA cDNA is obtained by first cutting pTPA3'cDNA with PuvII and EcoRI Isolating fragment 11 (1748 bp). Fragment 11 is then cut with Hgal to yield fragment 12 (209 bp) containing bases 594 to 802. To obtain the 3' portion of the cDNA, pTPA3'cDNA is digested with Pvul and the 6.3 kb fragment is isolated, treated with T4 polymerase, and partially digested with EcoRI to yield fragment 13 (1871 bp) containing bases 802 to 2230.
  • Plasmid pKC7 a vector containing ten restriction sites suitable for cloning DNA segments, Gene 7:79-82 (1979). Plasmid pKC7 is digested with BglII and Smal and treated with bacterial alkaline phosphatase to yield fragment 14 (4.8 kb) which is gel isolated.
  • Fragments 10,12,13 and 14 are ligated in a single ligation pool.
  • One noteworthy aspect of this strategy is the means by which the need for alkaline phosphatase treatment of the internal fragment is obviated.
  • multipiece ( ⁇ 4 fragments) ligations produce the desired construction with very low efficiency due to concatemerization of the fragments.
  • Treatment with alkaline phosphatase in the appropriate fashion minimizes this problem, resulting in a dramatic increase in efficiency of correct, multipiece assembly.
  • Hgal restriction endonuclease
  • the plasmid containing the complete cDNA sequence for TPA is designated pTPAcDNA (7.4 kb).
  • Block 1 Oligonucleotldes P1-P4, P8-P11 are annealed and ligated to form a double stranded segment which is ligated to a second segment comprised of oligonucleotldes P5-P7 and P12-P14.
  • the resulting block 1 contains the sequence coding for the finger domaln.
  • Block 1 Is cloned Into the BglII and SphI sites of pSK4 described in Preparation 1.
  • Oligonucleotldes P15-P18 and P19-P23 which contain the sequence coding for the finger domain are ligated together in a single step annealing and ligation to form block 2. and cloned into the SphI and Clal site of pBR322.
  • Block 3 Oligonucleotldes P24-P28, P34-P38 are annealed and ligated to form a double stranded segment which is ligated to a second segment comprised of oligonucleotldes P29-P33 and P39-P43.
  • the resulting block 3 contains the sequence coding for the kringle 1 domain.
  • Block 3 is cloned into the Clal and BamHI sites of pBR322.
  • Oligonucleotldes P44-P47 and P67-P70; P48-P51 and P71-P74; P52, P53, P92, P93 and, P75, P76, P94, P95; P57-P61 and F80-P84; and P62-P66 and P85-P89 are each annealed in 5 separate tubes into double stranded segments which are then pooled and ligated to form block 4.
  • Block 4 contains the DNA sequence coding for the kringle 2 domain. Block 4 is cloned into the BamHI and EcoRI sites of pBR322.
  • Example 2 The assembly of blocks 1-4 with the active site of the TPA cDNA. Charts 6-11.
  • the following example provides a summary of the steps needed to assemble the various synthetic blocks of Example 1 into a gene capable of encoding for a biologically active TPA.
  • Two prototype genes are described.
  • the plasmid pTPA-B1,2,3,4(a) has a gene encoding TPA which has no artificially-introduced endonuclease sites between the kringle 2 domain and the active site.
  • Plasmid pTPA-B,1,2,3,4 has a gene encoding TPA which does have artificiallyintroduced endonuclease restrition sites between kringle 2 and the active site.
  • Plasmid pSK4 is digested with Clal and SphI and the large 4.1 kb fragment 15 is isolated and ligated to the Block 1 fragment using a Clal/Xbal linker.
  • the ligation mixture is transformed into HB101 vising the calcium chloride transformation procedure described by Maniatis.
  • the transformants are screened with nick translated Block 1 fragments using the nick translation procedure described by Maniatis et al. Transformants hybridizing to the probe are then sequenced using the Sanger dideoxy sequencing technique to verify the correct sequence and orientation. This new transformant is denoted pTPA-Bl (4.25 kb).
  • Plasmid pTPA-B1 is digested with EcoRI and SphI and fragment 16 (450 bp) is isolated.
  • Plasmid pBR322 is digested EcoRI and Clal and the large fragment 17 (4.35 kb) is gel isolated. Fragments 16 and 17 are then ligated to the synthetic Sphl/Clal Block 2.
  • the ligation mixture is transformed into HB101 and the transformants screened with nick translated Block 2. Transformants hybridizing to the probe are sequenced to confirm that they contain Block 2 in its proper orientation. This construction is designated pTPA-B 1,2 (4.8 kb).
  • Plasmid pTPA-B 1.2(a) contains Hindlll and BglII restriction sites upstream from the finger and growth factor domains. Plasmid pTPA-B 1,2 is digested with Xbal and EcoRI and the large 4.5 kb fragment 18 is gel isolated and ligated to an oligonucleotide linker containing a Hindlll and BglII site. The ligation mixture is transformed into HB101 and transformants screened for the presence of the Hindlll/BglII sites. The new construction is designated pTPA-B 1.2(a) (4.5 kb).
  • Plasmid pTPA-B 1.2(a) is digested with Clal and BamHI and the large 4.0 kb fragment 19 is isolated. This fragment is ligated to the synthetic Clal/BamHI kringle 1 region comprising block 3 (270 bp) and transformed into HB101. The transformants were screened with nick translated block 3. Transformants hybridizing to Block 3 were sequenced to confirm the sequence and orientation. This new construction is designated pTPA-B 1,2,3 (4.3 kb).
  • pTPA-B 1,2,3,4a - Chart 10 This plasmid contains an entire prototype TPA gene encoding for a TPA analog having enzymatic activity. There are in this gene no changes to the interdomain region between kringle 2 and the active site. Construction of pTPA-B 1,2,3,4a (4.2 kb) requires several steps. Plasmid pTPAcDNA (Chart 5) is cut with Seal and fragment 20 (6.0 bp) encoding for the 3' end of the TPA gene is gel isolated. Plasmid pTPA-B 1,2,3 (Chart 9) is cut with Seal and BamHI to obtain fragment 21 (1100 bp) containing the Finger, Growth Factor and kringle 1 domains.
  • a third fragment 4a (230 bp) is obtained by cutting block 4 with BamHI and Seal.
  • the three fragments are ligated using T4 ligase to obtain pTPA-B 1,2,3,4a.
  • the TPA gene is cut out of pBr322 using Hindlll and Aatll to yield a 2.2 kb fragment which is subcloned into pUC-19.
  • Plasmid pUC-19 is commercially available from a variety of sources and contains a selection of restriction sites in its DNA sequence which makes TPA domain manipulation less cumbersome.
  • This plasmid contains an entire prototype TPA gene encoding for a enzymatlcally active TPA analog. In this analog all 4 domains and the active site are present with unique restriction sites engineered into all the interdomain regions including the region.between kringle 2 and the active site.
  • the plasmid is constructed by first cutting pTPA-B 1,2,3,4a with EcoRI and BamHI and isolating the large 3.7 kb fragment containing the Finger, Growth Factor and kringle 1 domains.
  • the synthetically created block 4 is obtained from its clone through a digestion with BamHI and partial digestion with EcoRI to yield intact block 4 having 560 kb.
  • T4 ligase The two fragments are ligated using T4 ligase to obtain pTPA-B 1,2,3,4.
  • Plasmid pTPA-B 1,2,3,4a and pTPA-B 1,2,3,4 can be used to construct a variety of synthetic TPA analogs.
  • Plasmid pTPA-B 1,2,3,4a is digested with EcoRV and partially with Hpal to digest the site at 334 but not at 724. The large fragment (6.9kb) is isolated and religated to form pFKlK2A. Plasmid pFKlK2A is then transformed into HB101 or some other suitable host. The plasmid is then screened for correct orientation and sequence.
  • Plasmid pTPA-B 1,2,3,4 is digested with Hpal. The large 6.5 kb fragment is isolated and religated to form pFK2A. The plasmid is transformed into HB101 or some other suitable host and screened for correct orientation and sequence. C. Construction of pFK2K2A - Chart 12 (deletion of growth factor and kringle 1 and duplication of kringle 2). Plasmid pTPA-B 1,2,3,4 (Chart 11) is digested with Hpal to obtain fragment 22 (6.5 kb) which is isolated.
  • a second sample of pTPA-B 1,2,3,4 is digested with Hpal and MstI and the resulting 560 bp fragment 23 containing the kringle 2 domain is isolated.
  • the Hpal digested FK2A fragment is blunt end ligated to the Hpal/MstI fragment to yield pFK2K2A (6.5 kb).
  • Plasmid pFK2K2A is then transformed into
  • TPA analogs can be accomplished in E coli by using the expression plasmid pTPA-B1,2 illustrated in chart 7, pTPA-B1 illustrated in Chart 6, or their equivalents. Any of the analogs can be placed within the Xbal and BamHI sites for expression.
  • pTPA-B 1,2 (Chart 7)
  • pFK2K2A (Chart 12) are both cut with Xbal and BamHI and fragments 24 (4.2 kb) and 25 (2.0 kb) are gel isolated. Fragments 24 and 25 are ligated to form expression plasmid pTPAExpl (6.2 kb).
  • Plasmid pTPAExpl contains a Trp promoter and operator and expression is constitutive. Culturing of E. coli is according to Maniatis (Supra). The E. coli cultures will not produce active TPA. The TPA produced by E. coli must be refolded into the native state. By following known cysteine reshuffling procedures one can obtain active TPA. US Pat. No. 4,511,502. Example 4. Expression in Eukaryotes. A. Expression of Human TPA in Yeast.
  • This example illustrates the construction of yeast expression plasmid p ⁇ l-FK2K2A having a MF ⁇ l promotor and pre-pro sequences. Culturing conditions and preferred host strains are also provided for the expression of TPA analogs in yeast.
  • Plasmid, p ⁇ l-ADHt is a multi-purpose expression vector for yeast. Restriction sites at convenient points have been engineered into its structure and control under the MF ⁇ l promoter is generally compatible with high levels of expression. The following steps describe the construction of p ⁇ l-ADHt. (Charts 14-18).
  • Plasmid pYIP31 is first cut with Smal and treated with bacterial alkaline phosphatase to yield fragment 26 (5.4 kb) which is isolated.
  • the 2 ⁇ plasmid of yeast is cut with Pstl and Xbal, filled with Klenow and fragment 27 (1.3 kb) is isolated. Fragments 26 and 27 are ligated using T4 DNA ligase to obtain pYRep3'B (6.7 kb).
  • pADHt-Charts 15-16 Plasmid pADHt (3.86 kb) is useful because it provides useful restriction sites to assemble a yeast expression vector.
  • Plasmid pGG400 is constructed from plasmids pBR322 and pML21 which are readily available to the public. J. Bacter. , 126:447-453 (1976). Specifically, the gene of pBR322 coding for tetracycline resistance is replaced with a section of pML21 coding for kanamycln resistance. Plasmid pBR322 is first cut with EcoRI and PvuII and the EcoRI overhang filled in with Klenow enzyme and isolated from an agarose gel to obtain fragment 28 (2.3 kb).
  • Plasmid pML21 is cut with PuvII to yield fragment 29 (1.7 kb) carrying the gene for resistance to kanamycln.
  • the ligation of a PuvII cut site with a filled EcoRI site will regenerate the EcoRI site after ligation.
  • the ligation of fragments 28 and 29 yields pGG400 which Is used to construct pADHt (Chart 15).
  • Plasmid pADHt is constructed by cutting pGG400 with PvuII and Xhol and treating with Klenow enzyme to obtain fragment 30 (3.5 kb) which is isolated.
  • the 3' end of yeast alcohol dehydrogenase I (ADHI) is obtained from pADHBC by first cutting with Hindi and BamHI, treating with T4 polymerase and isolating fragment 31 (0.36 kb).
  • Plasmid pADHBC is publicly available and fully described in J. Biol. Chem. 257:3018-1025 (1982). Fragments 30 and 31 are ligated to obtain pADHt among others and transformed into E. coli. Those transformants carrying pADHt will have regenerated BamHI and Xhol sites in their plasmids.
  • Plasmid pADHt-REPIII (6.2 kb) is a construction of pADHt and pYRep31B in which the URA3-REPIII-or1 cassette is placed into pADHt to facilitate expression and replication in yeast.
  • Plasmid pADHt-RE-PHI is useful for construction of expression vectors in yeast because the EcoRI-HindIII or EcoRI-Smal fragments can be replaced with a desired DNA fragment carrying appropriate yeast promoters or it can be used to provide a Sall-Xhol fragment carrying a replication origin, a selectable marker and the 3' end of the yeast URA3 gene.
  • Plasmid pADHt is modified by cutting with BamHI, filling the ends with Klenow enzyme and inserting an 8-mer Sail linker into the filled BamHI site. Plasmid pADHt (modified) is cut with SphI and the ends are filled with T4 polymerase to yield fragment 32 (3.8 kb).
  • Plasmid pYRep31B is cut with HindIII and fragment 33 (2.4 kb) is isolated containing the 3' end of URA3 and the 2 ⁇ RepIII region which is thought to increase stability and the origin of replication. Fragments 32 and 33 are ligated and the E. coli transformants having plasmids with an orientation of the URA3 gene allowing for a clockwise transcription are screened to obtain pADHt-REPIII. d. Construction of p ⁇ l-ADHt - Chart 18.
  • Plasmid pal is fully described by A. Singh, et al., Nucleic Acid Research, 11:4049-63 (1983) and J. Kurjan, et al., Cell, 30:933-943 (1983). Plasmid pADHt-REPIII is first cut with EcoRI and HindIII to yield fragment 34 (5.3 kb) which is isolated. Plasmid pal is also cut with EcoRI and HindIII to yield fragment 35 (1.2 kb) which is isolated. Fragments 34 and 35 are then ligated using T4 DNA ligase to obtain p ⁇ l-ADHt.
  • the preferred expression vector for the production of TPA analogs in yeast is designated p ⁇ l-FK2K2A having an MF ⁇ 1 promoter.
  • Blasmid pFK2K2A (Chart 12) is cut with BglII to yield fragment 36 (2.0 kb) which is gel isolated.
  • Plasmid p ⁇ l-ADHt is cut with HindIII and XhoI to yield fragment 37 (5.6 kb) and provides the transcription, the polyadenylation and translational sites.
  • the system described herein will terminate downstream from the mature TPA protein and the resulting product will have a few additional amino acids of yeast origin. To terminate translation at the precise end of the TPA gene, one can provide a termination codon.
  • the BglII site at the 5'-end can be manipulated either by inserting another linker or by a combination of Klenow (Pol I) and Mung Bean nuclease to create a HindIII site while maintaining the reading frame-in phase with the MF ⁇ 1 'pre-pro' sequences.
  • Klenow Poly I
  • Mung Bean nuclease Mung Bean nuclease
  • the BglII site of fragment 37 is partially filled using Klenow with adenosine and guanosine. The partially filled site is then made blunt with Mung Bean nuclease and ligated to the HindIII site of p ⁇ 1-ADHt.
  • Fragments 36 and 37 are ligated to yield pFK2K2A (7.6 kb).
  • Other analog TPA genes can also be inserted blunt-ended in the expression vector as long as the reading frame is maintained in phase with the yeast sequences.
  • TPA Analog from the Plasmid p ⁇ l-FK2K2A in Yeast Yeast strain YNN227 ( ⁇ ,ura3-52 trpl-289) are transformed with p ⁇ l-FK2K2A. The transformants are grown in glucose minimal medium (2% glucose, 0.7% yeast nitrogen base, 1% casamino acids, 40 ⁇ g/ml adenine, 50 ⁇ g/ml tryptophan) for 10 hours. Cells are then pelleted out by centrifugation. The cells are lysed by vortexing with glass beads. Quantities of TPA can be detected using Western Blotting techniques or radioimmunoassay or the casein enzymatic assay in agar described earlier for xenopus oocytes.
  • TPA can be isolated from yeast cells by first lyslng the cells with 0.5 mm glass beads followed by purification on an affinity column. Standard protein purification schemes can be applied to affect further purification.
  • Charts 20-22 The following example illustrates the preferred method for expressing p.FK2K2A in Chinese hamster ovary (CHO) cells.
  • CHO Chinese hamster ovary
  • a shuttle vector pSVCOW7 which replicates in both CHO and E. coli cells utilizing ampicillin resistance and dlhydrofolate reductase genes as markers in E. coli and CHO cells respectively.
  • Plasmid pSVCOW7 also provides the polyadenylation sequence from bovine growth hormone which is necessary for expression in CHO cells. Plasmid pSVCOW7 is first cleaved and a viral promoter and the TPA analog are inserted. Transformation culture conditions and extraction procedures for TPA expressed in CHO cells are also described below.
  • the starting plasmid pSV2dhfr (available from the American Type Culture Collection or prepared according to the procedure of S. Subramani,et al., "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40", Molecular and Cellular Biology 2:854-864 (Sept. 1981) is digested with BamHI and EcoRI to yield the fragment 38 (5.0 kb) containing the ampicillin resistance gene, the SV40 origin, and the dhfr gene.
  • the second portion of pSVCOW7 is obtained from plasmid p ⁇ GH2R2 which is digested with the same restriction endonucleases used to cleave pSV2dhfr to obtain fragment 39 containing the 3' end of genomic bovine growth hormone gene, i.e., BGH gDNA.
  • Plasmid p ⁇ GH2R2 is publicly available from an E. coll HB101 host, deposited with the Northern Regional Research Laboratories In Peoria, Illinois (NRRL B-15154). Fragments 38 and 39 are ligated to yield pSVC0W7 (7.1 kb).
  • TPA analog In order to conveniently insert a TPA analog into pSVCOW7 it is necessary to insert a convenient BamHI site within the leader sequence of TPA which is upstream from the mature protein sequence.
  • pTPAS'cDNA (Chart 5) is cut with Hgal and fragment 40 (517 bp) containing bases 78 to 593 is made flush with Klenow enzyme. The flush ends are ligated to a 10-mer BamHI linker and fragment 40 is cut with Narl to yield fragment 41 having bases 68 to 521 of the TPA cDNA.
  • Plasmid pTPA-cDNA (Chart 5) Is cut with Narl and BglII and fragment 42 (1644 bp) containing the 3' portion of the TPA cDNA is gel isolated. Fragments 41 and 42 are ligated to fragment 43 (4.3 kb) resulting from a BamHI and BglII digestion of pKC7 to yield pTPA-cDNA,BamHI (6.5 kb).
  • Plasmid pTPA-IE-PA containing a TPA modified cDNA having the native arrangement of TPA domains is capable of being expressed by CHO cells or capable of being used to facilitate the construction of alternative expression plasmid containing TPA analogs.
  • the assembly of pTPA-IE-PA is accomplished in two steps. First the TPA cDNA from pTPA-cDNA is inserted into pSVCOW7 and then the immediate early promoter of cytomegalovirus is inserted to initiate transcription of the TPA analog.
  • Plasmid pSVCOW7 is cut with EcoRI and PuvII and fragment 44 (600 bp) containing the polyadenylation sequence of bovine growth hormone extending from the PvuII site in the 3' most exon of the BGH gene, to the EcoRI site downstream from the 3' end.
  • EcoRI and PuvII and fragment 44 600 bp
  • Fragment 45 can be alternatively derived from the EcoRI/BamHI fragment from parent plasmid pSV2dhfr available from Bethesda Research Laboratories. Fragment 45 contains the origin of replication from pBR322 and an ampicillin resistance gene expressed in E. coli which allows for the selection of the plasmid in E. coli. The fragment also contains the mouse dihydrofolate reductase cDNA in a construction that allows expression in mammalian cells. Subramani, et al., Mol. Cell. Biol. 1:854-864 (1981).
  • the TPA cDNA is obtained from fragment 46 (1.9 kb) which is obtained from cutting pTPA-cDNA,BamHI with BamHI and Ball. Fragment 46 contains the full coding region from tPA cDNA.
  • the BamHI cut is in cDNA coding for the 5' untranslated sequences of the mRNA, and the Ball cut is in cDNA coding for the 3' untranslated region of the cDNA.
  • Fragments 44, 45 and 46 are ligated to form pTPA-PA (8.4 kb) which is a replication vector capable of shuttling between E coli and CHO cells.
  • Plasmid pTPA-PA is transformed into E coli.
  • pTPA-PA is converted into expression plasmid pTPA-IE-PA by inserting the immediate early gene promoter from human cytomegalovirus (CMV I.E. promoter).
  • CMV I.E. promoter is obtained from the PstI digestion of the CMV genome.
  • CMV I.E. major immediate early gene
  • Plasmid pTPA-PA constructed in Step 1, is cleaved with BamHI, and a Sau3AI fragment containing the CMV Immediate early promoter is ligated into the BamHI site. Plasmids containing the CMV promoter fragment in an orientation such that transcription from the promoter would synthesize an mRNA for TPA are identified by cleavage of the plasmids with Sad. The resulting plasmid is designated pTPA-IE-PA having the CMV I.E. promoter at the 5'-end of the TPA cDNA and the bGH polyadenylation signal on its 3'-end.
  • Step 1 involves the creation of pTPA-FK2K2A which contains the desired TPA analog, the polyadenylation signal sequence from BGH and the selectable markers and replicons of pSVCOW7 and Step 2 involves the insertion of the CMV I .
  • Step 2 involves the insertion of the CMV I .
  • E. promoter discussed earlier. While the example below describes the insertion of TPA analog FK2K2A, other analogs can be inserted using the same enzymes and procedures.
  • Plasmid pTPA-IE-PA (Chart 22) is cut with BamHI and BglII to yield fragment 47 containing the TPA leader sequence bases 1-188.
  • the polyadenylation signal sequence of BGH is obtained by cutting pSVCOW7 (Chart 20) with EcoRI and PvuII to yield fragment 48 (600bp).
  • the TPA analog sequence is obtained from cutting pFK2K2A (chart 12) with BglII and Ball to obtain fragment 49 (2.0 kb).
  • a second sample of pSVCOW7 is cut with EcoRI and BamHI to yield fragment 50 (5.8 kb) containing the markers and replicons of pSVCOW-7.
  • the four fragments are gel Isolated and ligated using T4 ligase to yield pTPA-FK2K2A (8.3 kb).
  • Step 2 Plasmid pTPA-FK2K2A is cut with BamHI and the Sau3A digested CMV-IE promoter sequence is inserted to form pTPA-IE-FK2K2A which is maintained in E. coli until transfeetion into CHO cells. (5) Transfection and Culturing of CHO Cells.
  • Plasmid pTPA-IE-FK2K2A is transfected into Chinese hamster ovary (CHO) cells deficient in dihydrofolate reductase(dhfr) using the calcium phosphate method for transfection of DNA into cells which is described in detail by Graham, et al. (in Introduction of Macromolecules into Viable Mammalian Cells, Alan R. Liss Inc., N.Y., 1980, pp. 3-25). The cell line used is the mutant DXB-11 originally available from L. Chasin, of Columbia University and completely described in Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980). The above methods for transfection relies on the fact that cells which incorporate the transfected plasmids are no longer dhfr deficient and will grow in Dulbecco's modified Eagle's medium plus proline.
  • TPA-IE-FK2K2A From the cells transfected with pTPA-IE-FK2K2A, clones are isolated, which, when grown in a monolayer for two days, synthesize at least 10 ng TPA per million cells. From cells with pIETPA-IPA-dhfr, clones are isolated which synthesize at least 100 ng TPA per million cells. Expression of TPA analog can be detected by radioimmunoassay, or Western blot techniques.
  • TPA analogs are purified according to the procedure of Rijken and Collen. Journal of Biological Chemistry 256:7035-7041 (1979).
  • the CHO cells containing the recombinant TPA analogs are grown in serum free media.
  • the culture media is harvested after 72 hours and applied to a zinc-chelate agarose column equilibrated with 0.02M Tris-HCl pH 7.5 containing 1.0M NaCl and 0.01% Tween 80.
  • the column is washed with the same buffer and the TPA analogs eluted with a linear gradient from 0 to 0.05M imidazole in the same buffer.
  • the fractions containing TPA analogs are pooled and applied to a concanavalin A-agarose column equilibrated with 0.01M phosphate buffer pH 7.5 containing 1.0M NaCl and 0.01% Tween 80. After washing the column with the same buffer, the TPA analogs are eluted with a linear gradient of the equilibration buffer to 0.01M phosphate buffer pH 7.5 containing 0.01% Tween 80, 0.4M D-methylmannoside and 2M potassium thiocyanate. The fractions containing TPA activity are pooled and solid KSCN is added to increase the KSCN concentration to 1.6M.
  • the fractions are concentrated approximately 10-fold and applied to a Sephadex G-150 column equilibrated with 0.01M phosphate buffer pH 7.5 containing 1.6M KSCN and 0.01% Tween 80.
  • the fractions containing the TPA activity are pooled, dialyzed against 0.1SM NaCl and 0.01% Tween 80 and stored at -80oC.
  • the following example relates to the expression of TPA in insect cell cultures. All procedures are detailed in Summers, M.D. and Smith, G.E., A Manual for Baculovirus Vectors and Insect Cell Culture Procedures published by the College of Agriculture, Texas Agricultural Experiment Station, Texas Agricultural Extension Service, College Station, Texas, 1986.
  • the starting plasmid pAc373 (7.1 kb) is a general baculovirus expression vector having a unique BamHI site immediately downstream from the polyhedron promoter for Autographa californica nuclear polyhedrosls virus (AcNPV) .
  • the polyhedron protein is a matrix protein that is nonessential for viral infection and replication in vitro.
  • the plasmid is available from Professor Max Summers of the Department of Entomology, Texas A&M University, College Station, Texas 77843 and is fully described in Molecular and Cell. Biology, 3(12):2156-2165 (1983).
  • Starting plasmid pAc373 is modified to accept the TPA analogs by inserting into the unique BamHI site a BglII site which is also unique. Plasmid pAc373 is first cut with BamHI and then treated with Mung bean nuclease to create blunt ends. BglII linkers are then ligated to the ends and the ends rejoined to yield pAc373,BglII. Plasmid pTPAcDNA,BamHI from chart 21 is fully digested with BamHI and partially digested with BglII to yield fragment 51 (1.95 Kb) coding for an intact TPA cDNA. Fragment 51 is gel isolated and inserted into the BglII site of pAc373,BglII to yield pAcTPA which is capable of expressing native TPA in S. frugiperda.
  • S. frugiperda (3) Transfection and culturing of S. frugiperda.
  • the TPA analogs are recombined with native ACNPV DNA by cotransfection in S. frugiperda.
  • S. frugiperda (SF9; ATCC CRL 1711) are cultured in Grace Media (Gibco Lab. Livonia, MI 48150), 10% fetal calf serum and supplemented with Difco Lactalbumin hydrolysolate and yeastolate.
  • the cells are cotransfected with AcNPV DNA and pAcTPAFK2K2A at 1 ⁇ /ml and 2 ⁇ /ml respectively. Resulting virus particles are obtained by collecting the media and removing cellular material by low speed centrifugation. The virus containing-media is then used to infect S.
  • frugiperda Subsequent infection of S. frugiperda using these viral particles which include both native viral DNA and DNA recombined with the cDNA coding for the FK2K2A TPA analog will result in some cells expressing the TPA analog instead of the polyhedron protein. Detection of infected cell colonies producing TPA analogs is determined by overlaying a monolayer of S. frugiperda that has been previously infected for one hour with serial dilutions of the viral containing media (10 -1 -10 -6 ). The cells are then overlayed with Grace media with 0.7% low melting point agar containing 6 mg/ml fibrlnogen and 0.5 units of thrombin. Those cells producing active TPA will form clear plaques around the foci of infection. Example 5.
  • Table 1 summarizes the results of two different in vitro tests, activity and antibody recognition.
  • Analogs FGK1K2A and FK2A form complexes with a plasminogen activator inhibitor from platelets (thrombin-induced platelet releasate).
  • the molecular weight of the analogs are about 62,000 and 40,000 daltons, respectively.
  • the molecular weights of the enzyme inhibitor complexes are approximately 110,000 and 85,000 daltons, respectively.
  • Example 6 Therapeutic application of TPA analogs.
  • TPA is known to be therapeutically useful for dissolving thrombi. The Lancet, pp. 1018-20 (Nov. 7, 1981); Science, 220:1181 (1983); and N. Eng. J. Med., 310:609 (1984).
  • Administration of TPA analogs to patients with coronary thrombi can be via intracoronary or intravenous routes according to the general procedures described in the above two references.
  • BLOCK 2 GROWTH FACTOR DOMAIN
  • pWl is treated with PvuII, Bglll and Klenow enzyme followed by purification of fragment 2 (323 bp) containing the trp promoter and part of TrpLE.
  • AmpR Ampicillin resistance
  • LacZ, LacY, LacA Genes in the lactose operon.
  • Ptrp Trp promoter/operator.
  • trpLE Fusion of trpL and trpE.
  • D Trp promoter/operator.
  • E TrpL ribosome binding site.
  • F trpLE and restriction sites.
  • AmpR Ampicillin resistance.
  • Fragment 6 is cloned into pBR322, cut with EcoRI and Clal to yield pSK4 (4.6 kb).
  • Plasmid pTPAH (5.7 kb) is obtained by cutting pBR322 with Pstl, tailing and inserting the 3' region of TPAcDNA having positions 1250 to 2530.
  • Plasmid pTPA80-1 (5.4 kb) is obtained by cutting pBR322 with Pstl, tailing and inserting cDNA of TPA having positions 550-1600.
  • Plasmid pTPAH and pTPA80-l are cut with Sad and Pvul and fragments 7 (1251 bp) and 8 (5.1 kb) respectively are gel isolated. The fragments are treated with bacterial alkaline phosphatase and ligated with T4 to form pTPA3' cDNA (6.3 kb) having bases 550-2530 of the TPAcDNA.
  • TetR Tetracycline resistance.
  • P 550-802 base positions of TPAcDNA.
  • A 803-2530 base positions of TPAcDNA.
  • N Untranslated 3' region of TPAcDNA.
  • Plasmid pTPA 5' cDNA is obtained by cutting pBR322 with Pstl, tailing and inserting the 5' region of TPAcDNA positions 1-750.
  • Plasmid pTPA 5' is cut with TaqI to yield fragment 9 (2194 bp) with is gel isolated and cut with BglII and Hgal to yield fragment 10 (405 bp) containing bases 188 to 593 of TPAcDNA (the mature TPA protein).
  • Plasmid pTPA 3' cDNA (Chart 4) is cut with PvuII and EcoRI and fragment 11 (1748 bp) is gel isolated. Fragment 11 is cut with Hgal to yield fragment 12 (209 bp) which is gel isolated and contains bases 594 to 802.
  • Plasmid pTPA 3' cDNA is cut with Pvul, the linear 6.3 kb fragment is treated with T4 polymerase to blunt the ends, and partially digested with EcoRI to yield fragment 13 (1871 kb) containing bases 802 to 2530 plus 123 bp of pBR322.
  • Plasmid pKC7 is cut with BglII and Smal, treated with bacterial alkaline phosphatase and fragment 14 (4.8 kb) is gel isolated.
  • T 5' portion of TPA cDNA.
  • P Middle portion of TPA cDNA.
  • A 3' portion of TPA cDNA.
  • N Untranslated 3' portion of TPA cDNA.
  • Plasmid pSK4 is cut with Clal and SphI to yield fragment 15 (4.1 kb) which is isolated and ligated to Block 1 containing the finger domain through a Clal/Xbal linker containing ATG.
  • D Trp promoter/operator.
  • E TrpL ribosome binding site.
  • F Finger domain.
  • AmpR Ampicillln resistance.
  • ATG Initiation codon.
  • Plasmid pTPA-B1 is cut with EcoRI and SphI to yield fragment 16 (450 bp) and Block 2 (100 bp) containing the growth factor domain, and is isolated from the appropriate clone using EcoRI and SphI.
  • Fragment 16 and Block 2 are ligated to fragment 17 (4.35 kb) derived from an EcoRI/Clal digestion of pBR322 to yield pTPA-B1,2 (4.8 kb).
  • P/O Trp promoter/operator.
  • RbS Trp ribosome binding site.
  • ATG Initiation codon.
  • F Finger domain.
  • AmpR Ampicillin resistance
  • Plasmid pTPA-B 1,2 is cut with Xbal and EcoRI to yield fragment 18 (4.5 kb) which was isolated and ligated to a linker containing a Hindlll site and BglII site to yield pTPA-Bl,2(a) (4.5 kb).
  • G Growth factor region.
  • AmpR Ampicillin resistance
  • Plasmid pTPA-B1,2(a) is cut with Clal/BamHI and fragment 19 (4.0 kb) is isolated and ligated with Block 3 (270 bp) containing kringle 1 and a Clal site upstream and a BamHI site downstream to yield pTPA3 (4.3 kb).
  • F Finger domain.
  • G Growth factor domain.
  • K Kringle 1.
  • AmpR AmpAcillin resistance.
  • Plasmid pTPAcDNA (Chart 5) is cut with Seal and fragment 20 (6.0 kb) containing the 3' portion of the TPA gene is gel isolated.
  • Plasmid pTPA-B1,2,3,4a is cut with EcoRI and BamHI.
  • the large fragment (3.7 kb) is ligated to block 4 (560 bp) obtained from the appropriate clone also cut with EcoRI (partial digestion) and BamHI to yield pTPA-B1,2,3,4.
  • AmpR Ampicillin resistance.
  • F Finger domain.
  • G Growth factor domain.
  • K Kringle 1 domain.
  • k Kringle 2 domain.
  • A 3' portion of TPAcDNA.
  • N Untranslated 3' portion of TPAcDNA.
  • Plasmid pTPA-B1,2,3,4a is cut with Hpal to yield fragment 22 (6.5 kb) which is isolated from a gel.
  • Ori Replication origin for pBR322.
  • AmpR Ampicillin resistance.
  • k Kringle 2 domain.
  • N Noncoding 3' sequence.
  • Plasmid pTPA-B1,2 (Chart 7) is cut with Xbal and BamHI and fragment 24 (4.2 kb) which is gel isolated.
  • Plasmid pFK2K2A (Chart 12) is cut with Xbal and BglII to yield fragment 25 (2.0 kb) which is gel isolated.
  • Fragments 24 and 25 are ligated to form pTPAExp 1 (6.2 kb); the BamHI and BglII are complementary but are not restored.
  • trpP/O Tryptophage promoter/operator.
  • RbS Ribosome binding site.
  • k kringle 2.
  • N Noncoding 3' sequence.
  • AmpR Ampicillln resistance.
  • Plasmid pYTP31 is cut with Smal and treated with bacterial alkaline phosphatase to yield fragment 26.
  • Plasmid pBR322 is cut with EcoRI and PvuII and ends filled in with Klenow enzyme to yield fragment 28 (2.3 kb).
  • AmpR Ampicillin resistance.
  • KmR Kanamycln resistance.
  • Plasmid pGG400 Is cut with Xhol and PvuII, treated with Klenow enzyme, and the resulting fragment 30 (3.5 kb) is isolated.
  • Plasmid pADHBC is cut with HincII and BamHI, the ends are filled with T4 ligase and the resulting fragment 31 (0.36 kb) is isolated.
  • AmpR Ampicillin resistance.
  • KmR Kanamycln resistance.
  • H ADHt 3' end.
  • Plasmid pADHt is modified by restriction with BamHI and ligation of an 8-mer Sall linker into the filled BamHI site.
  • Plasmid pADHt (modified) is cut with SphI and the ends filled in with T4 ligase to yield fragment 32 (3.8 kb).
  • Plasmid pyRep31B (Chart 16) is cut with Hindlll and the ends filled in with T4 ligase to yield fragment 33 (2.4 kb).
  • Fragments 32 and 33 are ligated using T4 ligase to obtain pADHt-RepIII (6.2 kb).
  • AmpR Ampicillin resistance
  • Plasmid pADHt-RepIII (Chart 15) is cut with EcoRI and Hindlll and fragment 34 (5.3 kb) is isolated.
  • MF ⁇ l Promoter and signal sequence for MF ⁇ l gene.
  • Plasmid pFK2K2A (Chart 12) is cut with Bglll to obtain fragment 36 (2.0 kb) which is gel isolated.
  • Plasmid p ⁇ l-ADHt is cut with Hindlll and Xhol; the ends are partially filled with Klenow enzyme in the presence of bases adenosine and guanosine, and treated with Mung Bean nuclease to yield fragment 37 (5.6 kb) which is gel isolated.
  • Fragments 36 and 37 are ligated to form p ⁇ l-FK2K2A (7.6 kb) .
  • MF ⁇ l Promoter and signal sequence for MF ⁇ l gene.
  • A Active site.
  • N Untranslated 3' sequence.
  • A Bovine growth hormone poly A tail.
  • G Genomic bovine growth hormone.
  • I Intron.
  • dhfr Dihydrofolate reductase.
  • SV40 SV40 promoter and origin of replication.
  • Plasmid pTPA5'cDNA (Chart 5, part a) is cut with Hga and fragment 40 (517 bp) is made flush with Klenow and ligated to a 10-mer BamHI linker. Fragment 40 is cut with Narl to yield fragment 41 (440 bp) having bases 78 to 518 of the TPAcDNA.
  • Plasmid pTPAcDNA (Chart 5) is cut with Narl and Bglll and fragment 42 (1644 bp) containing the 3' portion of TPAcDNA which is gel isolated.
  • T 5' portion of TPAcDNA.
  • P Middle portion of TPAcDNA.
  • A 3' portion of TPAcDNA.
  • Plasmid pSVCOW7 is cut with EcoRI and PvuII to yield fragment 44 (600 bp) containing the polyadenylation sequence of bovine growth hormone which is gel isolated.
  • Fragments 44, 45 and 46 are ligated to form pTPA-PA (8.4 kb).
  • Plasmid pTPA-PA is cut with BamHI and the CMV-IE promoter (760 bp) from a Pstl and Sau3AI digestion of the CMV genome is inserted to form pTPA-IE-PA.
  • AmpR Ampicillin resistance
  • Ori pBR322 origin of replication.
  • SV40/ori Simian virus origin of replication.
  • Mo/dhfr Mouse dihydrofolate reduetase marker.
  • T 5' region of TPAcDNA.
  • P Middle region of TPAcDNA.
  • A 3' region of TPAcDNA.
  • N Untranslated 3' region of TPAcDNA.
  • a Polyadenylation signal sequence.
  • Plasmid pSVCOW7 is cut with EcoRI and PvuII to yield fragment 48 (600 bp) containing the polyadenylation sequence of bovine growth hormone which is gel isolated.
  • Plasmid pSVCOW7 (Chart 20) is cut with EcoRI and BamHI to yield fragment 50.
  • Fragments 47, 48, 49 and 50 are ligated using T4 ligase to yield pTPAFK2K2A (8.3 kb).
  • Plasmid pTPAFK2K2A is cut with BamHI and the CMV-IE promoter (760 bp) from a Pstl and Sau3AI digestion of the CMV genome is inserted to form pTPA-IE-FK2K2A. CHART 23. (Continued)
  • AmpR Ampicillin resistance
  • Ori pBR322 origin of replication.
  • SV40 Simian virus origin of replication.
  • Mo/dhfr Mouse dihydrofolate reduetase marker.
  • CMV/Prom Cytomegalovirus promoter.
  • T 5' region of TPAcDNA.
  • N Untranslated 3' region of TPAcDNA.
  • a Polyadenylation signal sequence.
  • Plasmid pAc373 (7.1 kb) is cut with BamHI and treated with mung bean nuclease to create blunt ends to which Bglll linkers are added. The ends are rejoined to yield pAc373, Bglll.
  • Fragment 51 is inserted and ligated to the Bglll site of pAc373, Bglll to yield pAcTPA (9.05 kb)
  • T 5' portion of TPAcDNA.
  • N Untranslated 3' portion of TPAcDNA.
  • AmpR Ampicillin resistance.
  • Poly Polyhedrin protein gene. CHART 25. CONSTRUCTION OF pAc FK2K2A
  • Plasmid pFK2K2A (Chart 12) is cut with Bglll and the analog cDNA is gel isolated as fragment 53 (2.0 kb).
  • L Leader sequence.
  • F Finger domain.
  • k Kringle 2 domain.
  • A Active site domain.
  • N Untranslated 3' portion of TPAcDNA.
  • AmpR Ampicillin resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Les analogues d'un activateur de plasminogène tissulaire humain (TPA) sont des molécules semblables au TPA dont les régions de domaine natif ont été soit redisposées, éliminées, ajoutées ou combinées. Les analogues sont le produit de l'expression d'ADN recombinant également décrit dans cette invention. De plus, la présente invention décrit des plasmides de réplication et d'expression contenant les séquences d'ADN codant le TPA décrites ci-dessus et des microorganismes hôtes appropriés capables d'exprimer les analogues TPA après avoir été transformés avec un plasmide approprié.
EP87900529A 1985-12-20 1986-12-12 Analogues d'un activateur de plasminogene tissulaire (tpa) Pending EP0289508A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81160785A 1985-12-20 1985-12-20
US811607 1985-12-20
US90948286A 1986-09-19 1986-09-19
US909482 1986-09-19

Publications (1)

Publication Number Publication Date
EP0289508A1 true EP0289508A1 (fr) 1988-11-09

Family

ID=27123502

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87900529A Pending EP0289508A1 (fr) 1985-12-20 1986-12-12 Analogues d'un activateur de plasminogene tissulaire (tpa)
EP86309704A Expired - Lifetime EP0231624B1 (fr) 1985-12-20 1986-12-12 Analogues de l'activateur de plasminogène de tissu

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP86309704A Expired - Lifetime EP0231624B1 (fr) 1985-12-20 1986-12-12 Analogues de l'activateur de plasminogène de tissu

Country Status (12)

Country Link
EP (2) EP0289508A1 (fr)
JP (1) JPH0659223B2 (fr)
KR (2) KR880700856A (fr)
AT (1) ATE85081T1 (fr)
AU (1) AU600463B2 (fr)
DE (1) DE3687651T2 (fr)
DK (1) DK431887A (fr)
ES (1) ES2053449T3 (fr)
FI (1) FI97809C (fr)
GR (1) GR3007280T3 (fr)
NO (1) NO176921C (fr)
WO (1) WO1987003906A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK623186A (da) * 1985-12-23 1987-08-26 Chiron Corp Polypeptid med vaevsplasminogen-aktivator-virkning
EP0234051B1 (fr) * 1986-02-17 1991-12-11 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Mutants de l'activateur de plasminogène tissulaire; information recombinante génétique codant pour celui-ci et procédéde préparation de ces mutants, leur application et compositions pharmaceutiques
ATE90967T1 (de) * 1986-03-28 1993-07-15 Creative Biomolecules Inc Proteinanaloge des gewebs-plasminogenaktivators.
US5047241A (en) * 1986-07-11 1991-09-10 American Home Products Corporation Tris-Kringle plasminogen activator with novel K2 insert
US5580559A (en) * 1986-12-05 1996-12-03 Ciba-Geigy Corporation Hybrid plasminogen activator
US5242819A (en) * 1986-12-05 1993-09-07 Ciba-Geigy Corporation DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase
US5376547A (en) * 1987-01-30 1994-12-27 American Home Products Corporation Des-epidermal growth factor plasminogen activators
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US4963357A (en) * 1987-10-09 1990-10-16 Monsanto Company Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
US5100666A (en) * 1987-10-09 1992-03-31 Monsanto Company Modified tissue plasminogen activator K2K2SP
US5037752A (en) * 1987-10-09 1991-08-06 Monsanto Company Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277
EP0311589B1 (fr) * 1987-10-09 1994-03-23 Monsanto Company Activateur tissulaire du plasminogène modifié
US5244676A (en) * 1987-10-09 1993-09-14 Monsanto Company Modified tissue plasminogen activator with modified glycosylation site
DE3854195T2 (de) * 1987-10-29 1995-12-21 Yamanouchi Pharma Co Ltd Polypeptid-verbindungen.
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
AU619803B2 (en) * 1988-02-05 1992-02-06 Genzyme Corporation Rearranged tissue plasminogen activators and method for producing same
JPH03505276A (ja) * 1988-02-05 1991-11-21 ジェンザイム・コーポレーション 再配列された組織プラスミノーゲン活性化因子及びその産生方法
AU3064989A (en) * 1988-02-05 1989-08-25 Genzyme Corporation Modified gene sequences encoding modified tpa and products therefrom
US5346824A (en) * 1988-05-20 1994-09-13 Genentech, Inc. DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
DE3823805A1 (de) * 1988-07-14 1990-01-18 Basf Ag Neue polypeptide, ihre herstellung und verwendung
DE3825253A1 (de) * 1988-07-25 1990-02-01 Boehringer Mannheim Gmbh T-pa-derivat und seine herstellung
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3836200A1 (de) * 1988-10-24 1990-04-26 Boehringer Mannheim Gmbh Domaenenduplikations-muteine des gewebsplasminogen-aktivators (t-pa)
AU4502589A (en) * 1988-10-27 1990-05-14 Upjohn Company, The Thrombolytic agents with modified kringle domains
CA2007364A1 (fr) * 1989-01-17 1990-07-17 David J. Livingston Sequences de genes encodant des residus modifies situes dans le domaine protease du tpa
DE3927865A1 (de) * 1989-08-23 1991-02-28 Boehringer Mannheim Gmbh T-pa-mutante gk1l
DE69333127T2 (de) * 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
IL104355A (en) * 1993-01-10 2006-08-20 Yeda Res & Dev Tnf receptor promoter
US5795975A (en) * 1993-01-10 1998-08-18 Yeda Research And Development Co. Ltd. TNF receptor promoter
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79202B (fr) 1982-05-05 1984-10-22 Genentech Inc
ZA837173B (en) 1982-11-08 1984-05-30 Univ Case Western Reserve Genomic bovine growth hormone
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
EP0207589A1 (fr) * 1985-04-03 1987-01-07 Beecham Group Plc Enzyme fibrinolytique modifié
US4916071A (en) * 1985-08-14 1990-04-10 American Home Products Corporation Poly-kringle plasminogen activator
NZ217331A (en) * 1985-08-26 1989-05-29 Lilly Co Eli Tissue plasminogen activator derivatives and genetically engineered product

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8703906A1 *

Also Published As

Publication number Publication date
NO176921C (no) 1995-06-21
FI97809B (fi) 1996-11-15
FI882922A (fi) 1988-06-17
DE3687651T2 (de) 1993-06-24
ES2053449T3 (es) 1994-08-01
DE3687651D1 (de) 1993-03-11
DK431887D0 (da) 1987-08-19
EP0231624A1 (fr) 1987-08-12
FI97809C (fi) 1997-02-25
AU6770187A (en) 1987-07-15
KR950000303B1 (ko) 1995-01-13
DK431887A (da) 1987-08-19
EP0231624B1 (fr) 1993-01-27
FI882922A0 (fi) 1988-06-17
AU600463B2 (en) 1990-08-16
GR3007280T3 (fr) 1993-07-30
JPH0659223B2 (ja) 1994-08-10
NO873517D0 (no) 1987-08-20
WO1987003906A1 (fr) 1987-07-02
NO176921B (no) 1995-03-13
ATE85081T1 (de) 1993-02-15
NO873517L (no) 1987-08-20
JPH05344892A (ja) 1993-12-27
KR880700856A (ko) 1988-04-12

Similar Documents

Publication Publication Date Title
AU600463B2 (en) Tissue plasminogen activator (tpa) analogs
US5106741A (en) Tissue plasminogen activator (TPA) analogs
US5225537A (en) Methods for producing hybrid phospholipid-binding proteins
EP0266190B1 (fr) Expression de protéine C
US5516650A (en) Production of activated protein C
JP2610783B2 (ja) ポリクリングルプラスミノーゲン活性化因子をコードする遺伝子およびそれを含有するベクター
JPS62111690A (ja) ヒト―プロテインｃをコードする遺伝子
USRE37958E1 (en) DNA sequence coding for protein C
EP0277313B1 (fr) Activateur de plasminogène hybride
EP0263172B1 (fr) Analogues de proteine d'un activateur de plasminogene tissulaire
EP0299706A2 (fr) Activateur du plasminogène non glycosyte, et sa méthode de fabrication
EP0308716A2 (fr) Activateurs du plasminogène modifiés
CA2001343A1 (fr) Agents thrombolytique
US5242819A (en) DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase
US5700677A (en) Protein analogues of tissue plasminogen activator
US5409700A (en) Pharmaceutical compositions comprising modified and unmodified plasminogen activators
US5580559A (en) Hybrid plasminogen activator
USRE38981E1 (en) DNA sequence coding for protein C
JP2518832B2 (ja) 変形された組織プラスミノ−ゲンアクチベ−タ−
JPS63501841A (ja) 組織プラスミノ−ゲンアクチベ−タ−（ｔｐａ）同族体
EP0485504A1 (fr) Procedes de culture de cellules pour la production de proteine c activee.
EP0523296A1 (fr) Méthode de pliage de l'activateur tissulaire de plasminogène et ses dérivés
JPH02186986A (ja) 新規なポリペプチド、その製造及び用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19880707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 86309704.4/0231624 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 28.12.89.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: REHBERG, EDWARD, F.

Inventor name: MAROTTI, KEITH, R.

Inventor name: THERIAULT, NICOLE, Y.